A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA (SkybriGHt)

Ascendis Pharma

Status: Enrolling

Conditions: Growth Hormone Deficiency

Treatments: Other: No intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT05820672

ASND0037

Details and patient eligibility

About

The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care

Full description

Patients will be treated according to routine clinical practice, and no additional visits, examinations or tests will be required beyond those performed as part of routine clinical practice except for COAs.

Enrollment: 900 estimated patients

Sex: All

Ages: 1 to 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who are on treatment with SKYTROFA (lonapegsomatropin)
• Patients being clinically managed in USA
• Patients with an appropriate written informed consent/assent as applicable for the age of the patient

Exclusion criteria

• Patients participating in any interventional clinical study

Trial design

900 participants in 1 patient group

Patients on SKYTROFA Treatment

Description:

Patients on SKYTROFA Treatment managed in USA with appropriate written Informed Consent

Treatment:

Other: No intervention